<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03613688</url>
  </required_header>
  <id_info>
    <org_study_id>079-007</org_study_id>
    <nct_id>NCT03613688</nct_id>
  </id_info>
  <brief_title>Effects of Deepure(Pu-erh Tea Extract) on Glycemic Control</brief_title>
  <official_title>Effects of Deepure(Pu-erh Tea Extract) on Glycemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tasly Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Natural Immune Systems Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tasly Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, controlled, cross-over study on the effects of consumption of Deepure&#xD;
      puerh tea extract (PTE) on glucose tolerance and metabolic markers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will involve consuming three different doses: 1 gram, 1.5 grams, and 2 grams, and&#xD;
      will be given in warm water, with a bland meal. The effects on glucose and insulin after&#xD;
      consumption will be evaluated.The subjects will be randomly assigned to one of four groups&#xD;
      with different sequences.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">September 20, 2018</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-prandial glucose response</measure>
    <time_frame>From baseline to 30, 60, 90, 120, and 180 minutes</time_frame>
    <description>Change in blood glucose leve after consuming test meal with and without Pu'er tea</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Glucose Metabolism Disorders</condition>
  <arm_group>
    <arm_group_label>Deepure Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Visit 3: Warm water without Deepure; Visit 4: Warm water with 1 g Deepure; Visit 5: Warm water with 1.5 g Deepure; Visit 6: Warm water with 2 g Deepure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deepure Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Visit 3: Warm water with 1 g Deepure; Visit 4: Warm water with 1.5 g Deepure; Visit 5: Warm water with 2 g Deepure; Visit 6: Warm water without Deepure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deepure Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Visit 3: Warm water with 1.5 g Deepure; Visit 4: Warm water with 2 g Deepure; Visit 5: Warm water without Deepure; Visit 6: Warm water with 1 g Deepure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deepure Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Visit 3: Warm water with 2 g Deepure; Visit 4: Warm water without Deepure; Visit 5: Warm water with 1 g Deepure; Visit 6: Warm water with 1.5 g Deepure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Deepure</intervention_name>
    <description>Pu'erh Tea extract</description>
    <arm_group_label>Deepure Group A</arm_group_label>
    <arm_group_label>Deepure Group B</arm_group_label>
    <arm_group_label>Deepure Group C</arm_group_label>
    <arm_group_label>Deepure Group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women;&#xD;
&#xD;
          -  Aged 18-70 years;&#xD;
&#xD;
          -  BMI between 20-30;&#xD;
&#xD;
          -  Fasting blood glucose at screening between 71-125 mg/dL. both inclusive.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Taking dietary supplements judged to interfere with the effects of Deepure on glucose&#xD;
             metabolism (for example: cinnamon extract; chromium picolinate; mulberry extract;&#xD;
             bitter melon extract, green tea extracts, black tea extracts, pu-erh tea);&#xD;
&#xD;
          -  Participation in other clinical trials, involving an investigational product or&#xD;
             lifestyle change, during the last month;&#xD;
&#xD;
          -  Participation in another research study during this trial, involving an&#xD;
             investigational product or lifestyle change; Taking prescription medication known to&#xD;
             affect glucose metabolism;&#xD;
&#xD;
          -  Taking over-the-counter medication known to affect glucose metabolism;&#xD;
&#xD;
          -  Drinking 3 or more cups of tea daily;&#xD;
&#xD;
          -  Unwilling to abstain from drinking tea for 24 hours before clinic visits; (if a person&#xD;
             drinks tea within 24 hours of a clinic visit, the person's visit will be&#xD;
             re-scheduled);&#xD;
&#xD;
          -  Consuming 2 or more drinks of alcohol per day;&#xD;
&#xD;
          -  Unwilling to abstain from drinking alcohol for 10 hours before clinic visits;&#xD;
&#xD;
          -  Diagnosed with diabetes Type I; Taking medication for diabetes Type II;&#xD;
&#xD;
          -  Diagnosed with the thyroid disorder Hashimoto's disease;&#xD;
&#xD;
          -  Past major surgery to your stomach or intestines (minor surgery not a problem such as&#xD;
             hernia repair, appendix removal, gallbladder removal);&#xD;
&#xD;
          -  Currently taking cholesterol-lowering medication (for example: statins);&#xD;
&#xD;
          -  Currently taking coumadin;&#xD;
&#xD;
          -  Major trauma within the past 6 months;&#xD;
&#xD;
          -  Major surgery within the past 6 months;&#xD;
&#xD;
          -  Severe chronic infectious disease (such as HIV, chronic hepatitis);&#xD;
&#xD;
          -  Active depression;&#xD;
&#xD;
          -  Self-reported eating disorders;&#xD;
&#xD;
          -  History of drug abuse during past two years;&#xD;
&#xD;
          -  Currently going through intense stressful events or life changes;&#xD;
&#xD;
          -  Women of child-bearing potential: Pregnant, breast-feeding, or trying to become&#xD;
             pregnant;&#xD;
&#xD;
          -  Women of child-bearing potential: Not using effective contraception;&#xD;
&#xD;
          -  Food allergies or sensitivities to tea.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gitte Jensen</last_name>
    <phone>(541) 884-0112</phone>
    <email>gitte@nislabs.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>NIS labs</name>
      <address>
        <city>Klamath Falls</city>
        <state>Oregon</state>
        <zip>97601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gitte Jensen</last_name>
      <phone>541-884-0112</phone>
      <email>gitte@nislabs.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>July 26, 2018</study_first_submitted>
  <study_first_submitted_qc>August 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>October 29, 2018</last_update_submitted>
  <last_update_submitted_qc>October 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

